|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 6 (September 15), 1999:
pp. 2128-2134
The Cellular Labile Iron Pool and Intracellular Ferritin in K562 Cells
Abraham M. Konijn,
Hava Glickstein,
Boris Vaisman,
Esther G. Meyron-Holtz,
Itzchak N. Slotki, and
Z. Ioav Cabantchik
From the Department of Human Nutrition and Metabolism, Faculty of
Medicine, and Department of Biological Chemistry, Institute of Life
Sciences, Hebrew University of Jerusalem and Nephrology Unit, Shaare
Zedek Medical Center, Jerusalem, Israel.
The labile iron pool (LIP) harbors the metabolically active and
regulatory forms of cellular iron. We assessed the role of intracellular ferritin in the maintenance of intracellular LIP levels.
Treating K562 cells with the permeant chelator isonicotinoyl salicylaldehyde hydrazone reduced the LIP from 0.8 to 0.2 µmol/L, as
monitored by the metalo-sensing probe calcein. When cells were reincubated in serum-free and chelator-free medium, the LIP partially recovered in a complex pattern. The first component of the LIP to
reappear was relatively small and occurred within 1 hour, whereas the
second was larger and relatively slow to occur, paralleling the decline
in intracellular ferritin level (t1/2= 8 hours). Protease inhibitors such as leupeptin suppressed both the changes in ferritin levels and cellular LIP recovery after chelation. The changes in the
LIP were also inversely reflected in the activity of iron regulatory
protein (IRP). The 2 ferritin subunits, H and L, behaved qualitatively
similarly in response to long-term treatments with the iron chelator
deferoxamine, although L-ferritin declined more rapidly, resulting in a
4-fold higher H/L-ferritin ratio. The decline in L-ferritin, but not
H-ferritin, was partially attenuated by the lysosomotrophic agent,
chloroquine; on the other hand, antiproteases inhibited the degradation
of both subunits to the same extent. These findings indicate that,
after acute LIP depletion with fast-acting chelators, iron can be
mobilized into the LIP from intracellular sources. The underlying
mechanisms can be kinetically analyzed into components associated with
fast release from accessible cellular sources and slow release from
cytosolic ferritin via proteolysis. Because these iron forms are known
to be redox-active, our studies are important for understanding the
biological effects of cellular iron chelation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Kakhlon, H. Manning, W. Breuer, N. Melamed-Book, C. Lu, G. Cortopassi, A. Munnich, and Z. I. Cabantchik
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
Blood,
December 15, 2008;
112(13):
5219 - 5227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Boddaert, K. H. Le Quan Sang, A. Rotig, A. Leroy-Willig, S. Gallet, F. Brunelle, D. Sidi, J.-C. Thalabard, A. Munnich, and Z. I. Cabantchik
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Blood,
July 1, 2007;
110(1):
401 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Z. Kidane, E. Sauble, and M. C. Linder
Release of iron from ferritin requires lysosomal activity
Am J Physiol Cell Physiol,
September 1, 2006;
291(3):
C445 - C455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schranzhofer, M. Schifrer, J. A. Cabrera, S. Kopp, P. Chiba, H. Beug, and E. W. Mullner
Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis
Blood,
May 15, 2006;
107(10):
4159 - 4167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wang, C. Fillebeen, G. Chen, B. Andriopoulos, and K. Pantopoulos
Sodium Nitroprusside Promotes IRP2 Degradation via an Increase in Intracellular Iron and in the Absence of S Nitrosylation at C178.
Mol. Cell. Biol.,
March 1, 2006;
26(5):
1948 - 1954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Kalinowski and D. R. Richardson
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Pharmacol. Rev.,
December 1, 2005;
57(4):
547 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Glickstein, R. Ben El, M. Shvartsman, and Z. I. Cabantchik
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
Blood,
November 1, 2005;
106(9):
3242 - 3250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Hou and A. H.-J. Wang
Mithramycin forms a stable dimeric complex by chelating with Fe(II): DNA-interacting characteristics, cellular permeation and cytotoxicity
Nucleic Acids Res.,
March 1, 2005;
33(4):
1352 - 1361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sturm, U. Bistrich, M. Schranzhofer, J. P. Sarsero, U. Rauen, B. Scheiber-Mojdehkar, H. de Groot, P. Ioannou, and F. Petrat
Friedreich's Ataxia, No Changes in Mitochondrial Labile Iron in Human Lymphoblasts and Fibroblasts: A DECREASE IN ANTIOXIDATIVE CAPACITY?
J. Biol. Chem.,
February 25, 2005;
280(8):
6701 - 6708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bunda, N. Kaviani, and A. Hinek
Fluctuations of Intracellular Iron Modulate Elastin Production
J. Biol. Chem.,
January 21, 2005;
280(3):
2341 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-S. Zhang, A. D. Sheftel, and P. Ponka
Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria
Blood,
January 1, 2005;
105(1):
368 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E.R. Kartikasari, N. A. Georgiou, F. L.J. Visseren, H. van Kats-Renaud, B. S. van Asbeck, and J. J.M. Marx
Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells
Arterioscler Thromb Vasc Biol,
December 1, 2004;
24(12):
2257 - 2262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Atamna and W. H. Frey II
A role for heme in Alzheimer's disease: Heme binds amyloid {beta} and has altered metabolism
PNAS,
July 27, 2004;
101(30):
11153 - 11158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Torti and S. V. Torti
Regulation of ferritin genes and protein
Blood,
May 15, 2002;
99(10):
3505 - 3516.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Kakhlon, Y. Gruenbaum, and Z. I. Cabantchik
Repression of ferritin expression increases the labile iron pool, oxidative stress, and short-term growth of human erythroleukemia cells
Blood,
May 1, 2001;
97(9):
2863 - 2871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.G. Meyron-Holtz, B. Vaisman, Z.I. Cabantchik, E. Fibach, T.A. Rouault, C. Hershko, and A.M. Konijn
Regulation of Intracellular Iron Metabolism in Human Erythroid Precursors by Internalized Extracellular Ferritin
Blood,
November 1, 1999;
94(9):
3205 - 3211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Thomson, J. T. Rogers, and P. J. Leedman
Thyrotropin-releasing Hormone and Epidermal Growth Factor Regulate Iron-regulatory Protein Binding in Pituitary Cells via Protein Kinase C-dependent and -independent Signaling Pathways
J. Biol. Chem.,
October 6, 2000;
275(41):
31609 - 31615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cozzi, B. Corsi, S. Levi, P. Santambrogio, A. Albertini, and P. Arosio
Overexpression of Wild Type and Mutated Human Ferritin H-chain in HeLa Cells. IN VIVO ROLE OF FERRITIN FERROXIDASE ACTIVITY
J. Biol. Chem.,
August 11, 2000;
275(33):
25122 - 25129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Romeo, L. Christen, E. G. Niles, and D. J. Kosman
Intracellular Chelation of Iron by Bipyridyl Inhibits DNA Virus Replication. RIBONUCLEOTIDE REDUCTASE MATURATION AS A PROBE OF INTRACELLULAR IRON POOLS
J. Biol. Chem.,
June 22, 2001;
276(26):
24301 - 24308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
